We Might See A Profit From Ayurcann Holdings Corp. (CSE:AYUR) Soon

By
Simply Wall St
Published
November 08, 2021
CNSX:AYUR
Source: Shutterstock

Ayurcann Holdings Corp. (CSE:AYUR) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ayurcann Holdings Corp. provides post-harvest outsourcing solutions to licensed cannabis producers in Canada. On 30 June 2021, the CA$21m market-cap company posted a loss of CA$278k for its most recent financial year. As path to profitability is the topic on Ayurcann Holdings' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

See our latest analysis for Ayurcann Holdings

Expectations from some of the Canadian Pharmaceuticals analysts is that Ayurcann Holdings is on the verge of breakeven. They expect the company to post a final loss in 2021, before turning a profit of CA$2.4m in 2022. The company is therefore projected to breakeven around a year from now or less! We calculated the rate at which the company must grow to meet the consensus forecasts predicting breakeven within 12 months. It turns out an average annual growth rate of 95% is expected, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

earnings-per-share-growth
CNSX:AYUR Earnings Per Share Growth November 9th 2021

Given this is a high-level overview, we won’t go into details of Ayurcann Holdings' upcoming projects, however, take into account that by and large a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital prudently, with debt making up 0.8% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on Ayurcann Holdings, so if you are interested in understanding the company at a deeper level, take a look at Ayurcann Holdings' company page on Simply Wall St. We've also put together a list of important aspects you should further examine:

  1. Valuation: What is Ayurcann Holdings worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Ayurcann Holdings is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Ayurcann Holdings’s board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.